Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis

Yui Kanazawa; Yuka Yamashita; Mitsuhiro Fujiwara; Michiko Muraoka; Kana Washio; Kiichiro Kanemitsu; Hisashi Ishida; Takae Nakano; Miho Yamada; Keizo Horibe; Takehiro Tanaka; Tadashi Yoshino; Akira Shimada

doi:10.18926/AMO/54815

Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis

Yui Kanazawa, Yuka Yamashita, Mitsuhiro Fujiwara, Michiko Muraoka, Kana Washio, Kiichiro Kanemitsu, Hisashi Ishida, Takae Nakano, Miho Yamada, Keizo Horibe, Takehiro Tanaka, Tadashi Yoshino, Akira Shimada

Research output: Contribution to journal › Article › peer-review

Abstract

Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10–30 of cases of non-Hod-gkin lymphoma, and the ALCL99 study reported 60–75 disease-free survival; however, a relatively high relapse rate was observed (25–30 ). We report 2 patients with Stage III ALCL who relapsed 6–18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identiﬁed the nuc-leophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the ﬁrst diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be rela-tively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneﬁcial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the ﬁrst diag-nostic bone marrow sample

Original language	English
Pages (from-to)	503-506
Number of pages	4
Journal	Acta medica Okayama
Volume	70
Issue number	6
DOIs	https://doi.org/10.18926/AMO/54815
Publication status	Published - 2016

Keywords

ALCL
NPM-ALK fusion
lymphoma

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.18926/AMO/54815

Cite this

Kanazawa, Y., Yamashita, Y., Fujiwara, M., Muraoka, M., Washio, K., Kanemitsu, K., Ishida, H., Nakano, T., Yamada, M., Horibe, K., Tanaka, T., Yoshino, T., & Shimada, A. (2016). Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis. Acta medica Okayama, 70(6), 503-506. https://doi.org/10.18926/AMO/54815

Kanazawa, Y, Yamashita, Y, Fujiwara, M, Muraoka, M, Washio, K, Kanemitsu, K, Ishida, H, Nakano, T, Yamada, M, Horibe, K, Tanaka, T, Yoshino, T & Shimada, A 2016, 'Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis', Acta medica Okayama, vol. 70, no. 6, pp. 503-506. https://doi.org/10.18926/AMO/54815

@article{deadaae3cab94121a5d2e74366691859,

title = "Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis",

abstract = "Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10–30 of cases of non-Hod-gkin lymphoma, and the ALCL99 study reported 60–75 disease-free survival; however, a relatively high relapse rate was observed (25–30 ). We report 2 patients with Stage III ALCL who relapsed 6–18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identiﬁed the nuc-leophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the ﬁrst diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be rela-tively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneﬁcial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the ﬁrst diag-nostic bone marrow sample",

keywords = "ALCL, NPM-ALK fusion, lymphoma",

author = "Yui Kanazawa and Yuka Yamashita and Mitsuhiro Fujiwara and Michiko Muraoka and Kana Washio and Kiichiro Kanemitsu and Hisashi Ishida and Takae Nakano and Miho Yamada and Keizo Horibe and Takehiro Tanaka and Tadashi Yoshino and Akira Shimada",

note = "Funding Information: Supported in part by a Grant-in-Aid for Cancer Research and a grant for Clinical Cancer Research and Research on Children and Families from the Ministry of Health, Labor and Welfare of Japan. We thank all of the medical staff who participated in the patients? care and contributed to the collection of the biological samples and clinical information Publisher Copyright: {\textcopyright} 2016. by Okayama University Medical School.",

year = "2016",

doi = "10.18926/AMO/54815",

language = "English",

volume = "70",

pages = "503--506",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "6",

}

TY - JOUR

T1 - Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis

AU - Kanazawa, Yui

AU - Yamashita, Yuka

AU - Fujiwara, Mitsuhiro

AU - Muraoka, Michiko

AU - Washio, Kana

AU - Kanemitsu, Kiichiro

AU - Ishida, Hisashi

AU - Nakano, Takae

AU - Yamada, Miho

AU - Horibe, Keizo

AU - Tanaka, Takehiro

AU - Yoshino, Tadashi

AU - Shimada, Akira

N1 - Funding Information: Supported in part by a Grant-in-Aid for Cancer Research and a grant for Clinical Cancer Research and Research on Children and Families from the Ministry of Health, Labor and Welfare of Japan. We thank all of the medical staff who participated in the patients? care and contributed to the collection of the biological samples and clinical information Publisher Copyright: © 2016. by Okayama University Medical School.

PY - 2016

Y1 - 2016

N2 - Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10–30 of cases of non-Hod-gkin lymphoma, and the ALCL99 study reported 60–75 disease-free survival; however, a relatively high relapse rate was observed (25–30 ). We report 2 patients with Stage III ALCL who relapsed 6–18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identiﬁed the nuc-leophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the ﬁrst diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be rela-tively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneﬁcial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the ﬁrst diag-nostic bone marrow sample

AB - Childhood anaplastic large cell lymphoma (ALCL) accounts for approx. 10–30 of cases of non-Hod-gkin lymphoma, and the ALCL99 study reported 60–75 disease-free survival; however, a relatively high relapse rate was observed (25–30 ). We report 2 patients with Stage III ALCL who relapsed 6–18 months after the end of ALCL99 chemotherapy. A retrospective molecular analysis identiﬁed the nuc-leophosmin (NPM)-anaplastic lymphoma kinase (ALK) fusion gene in the ﬁrst diagnostic bone marrow samples taken from both patients. However, antibodies against the ALK protein appeared to be rela-tively low in the serum of both patients (×100 and ×750). An increase in chemotherapy intensity may be beneﬁcial if Stage III ALCL patients are shown to be NPM-ALK chimera-positive in the ﬁrst diag-nostic bone marrow sample

KW - ALCL

KW - NPM-ALK fusion

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85013848085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013848085&partnerID=8YFLogxK

U2 - 10.18926/AMO/54815

DO - 10.18926/AMO/54815

M3 - Article

C2 - 28003677

AN - SCOPUS:85013848085

SN - 0386-300X

VL - 70

SP - 503

EP - 506

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 6

ER -

Two Relapsed Stage III Childhood Anaplastic Large Cell Lymphoma Patients with NPM-ALK Fusion in Bone Marrow from Initial Diagnosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this